NCT02492776View on ClinicalTrials.gov

A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 7, 2015

Primary Completion Date

August 4, 2015

Study Completion Date

August 11, 2015

Conditions
Healthy
Interventions
DRUG

Omeprazole

20 mg oral capsules administered once daily for 8 days

DRUG

Gefapixant

Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days

DRUG

Gefapixant

Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY